Navigation Links
HGS unveils positive QOL results from Phase 2B trial of Albuferon for hepatits C
Date:11/5/2007

ROCKVILLE, Maryland November 5, 2007 Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the final quality-of-life results from a Phase 2b clinical trial of the investigational drug, Albuferon (albinterferon alfa-2b), in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. The study demonstrated that patients in the Albuferon treatment groups reported fewer missed days of work and less impairment of health-related quality of life on treatment compared to the Pegasys (peginterferon alfa-2a) group.

The final Phase 2b quality-of-life results are being presented this week at the 58 th AASLD Annual Meeting in Boston. In two additional press releases issued by HGS today, the Company announced the full presentations at AASLD of efficacy and safety data from the Phase 2b trial of Albuferon in treatment-naive patients, and results from the Phase 2 trial of Albuferon in combination with ribavirin in patients who did not respond to prior therapy.

Patients undergoing treatment for chronic hepatitis C often find it challenging to go to work or participate in other normal daily activities, especially in the days following dose administration, said Stephen Pianko, M.D., F.R.A.C.P., Ph.D., Monash University, Melbourne, Australia. The results of the Phase 2b trial suggest that Albuferon may have the potential to offer a therapeutic alternative with fewer lost days of work and less impairment of health-related quality of life on treatment, compared with peginterferon alfa-2a, with at least comparable efficacy and safety. We look forward to further evaluation of Albuferons impact on patient quality of life in the ongoing Phase 3 trials.

In the open-label, multi-center, active-controlled Phase 2b trial, 458 treatment-naive patients with genotype 1 chronic hepatitis C were randomized to four treatment groups: Albuferon 900 mcg every two weeks, Albuferon 1200 mcg every two weeks, Albuferon 1200 mcg every fou
'/>"/>

Contact: Jerry Parrott
301-315-2777
Edelman Public Relations
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
2. Wellcorps International Unveils New Nutritional Supplements
3. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
4. Rice unveils $100 million initiative for world health technology
5. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
6. The Well Life Center in Mesa Unveils The 10 Healing Secrets to Health & Longevity Lecture. Proceeds Benefit The Arizona Special Olympics
7. Cleveland Clinic Unveils Top 10 Medical Innovations For 2008
8. National Domestic Violence Hotline Unveils 10-Year Blueprint to Significantly Reduce Domestic Violence in America
9. GainSpan Unveils Wi-Fi(R) Sensor Network Solution With Years of Battery Life
10. U.S. Unveils Database of Genetic, Clinical Research
11. Saks Fifth Avenue Unveils Five Magical Holiday Gifts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...all/ -- Heska Corporation,(Nasdaq: HSKA ) today... of,Security Analysts, 12th Annual Biotech and Sp...1177 Avenue of the Americas, 2nd Floor in New York...:35 a.m. Eastern Time (7:35 a.m.,Mountain Time) a...weeks,following the presentation through a link u...
(Date:11/21/2008)...ique to combat cancer, study says, , ,...archers have discovered that some cancer cells use...ight lead to new treatments that starve and kill t...ells in the body need to produce energy. They do t...uires oxygen. Compared with normal cells, tumor ce...
(Date:11/21/2008)...ire/ -- U.S. News & World Report and the Natio...BlueChoice(R) HealthPlan of South Carolina in the ...ished in U.S. News & World Report,s issue this...ks the nation,s best health plans based on clinica...ion scores. NCQA and U.S. News & World Report ...
(Date:11/21/2008)...production of neural stem cells , , FRID...mice, exercise appears to reverse the decline in t...h aging, Taiwanese researchers report. , This r...ave off aging appears to be due to exercise,s abil...or the production of new brain cells. , "As we...
Breaking Medicine News(10 mins):Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Exercise Keeps the Brain Young 2
...d villages have given birth to babies with eyesigh...med the air and water pollution //caused by coal m... Giridih district, around 200 km from here, were b...Saturday. The babies were admitted to an eye hospi...
...t outbreak of Avian Influenza in Pakistan. // In v...th-Western States bordering Pakistan were immediat...g areas especially to check informal/illegal trade...livestock and livestock products; intensify animal...
...ce and Medicine in Cricket (WCSMC), which is endor...as hosted in Barbados from the 4th to 7th April 20...ne consultant at the Manipal Hospital, Bangalore i... conference as a faculty from India. These scie...
... concerns of successive Australian governments, a ...on says //that the health of aborigines lags an ap...Aboriginal and Torres Strait Islander people have ...an their fellow countrymen on every indicator of h...
Other Medicine News:Health News:Women Deliver Babies With Eye Defects in Jharkhand Villages 2Health News:Steps To Prevent Out-Break Of Bird Flu 2Health News:Steps To Prevent Out-Break Of Bird Flu 3Health News:Cricket Science and Medicine Congress in Barbados 2Health News:Cricket Science and Medicine Congress in Barbados 3Health News:Cricket Science and Medicine Congress in Barbados 4Health News:Cricket Science and Medicine Congress in Barbados 5Health News:Aborigines Century Behind the Health of Colonizers, WHO Report 2
(Date:11/20/2008)...N, Nov. 20 PAREXEL Inter...global biopharmaceutical services provider, today ...ru to provide regulatory consulting and clinical r...u office, PAREXEL now has locations throughout fiv...rica, which also include Argentina, Brazil, Chile,...
(Date:11/19/2008)... , Study did not achieve statistical significa...FirstCall/ -- Pharmos Corporation (Nasdaq: PARS ...al trial of its topical NanoEmulsion (NE) drug del...thanolamine. , , The multi-center, randomiz...ated the safety and efficacy of the Company,s 3% D...
(Date:11/19/2008)...gers $5 Million Payment from Roche- , , MON...ory Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... for its Phase 2 trial of R3487/MEM 3454, its lead...impairment associated with schizophrenia (CIAS). ...se 2 trial, triggering a $5.0 million payment from...
(Date:11/18/2008)...OWNE, Va., Nov. 18 Fort...hered at a November national forum to consider cut...blic health and national economy from outbreaks of...unced today. , , Among those innovations: ,...y American kitchen table that detects highly conta...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 11973 1Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 11973 2Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 11973 3New study shows extent of harmful human influences on global ecosystems 11971 1New study shows extent of harmful human influences on global ecosystems 11971 2Cell phone cancer link found by Tel Aviv University scientist 11969 1Cell phone cancer link found by Tel Aviv University scientist 11969 2Choking Game Turned Deadly for 82 Youths 11967 1Choking Game Turned Deadly for 82 Youths 11967 2Choking Game Turned Deadly for 82 Youths 11967 3
ACL 1000 is an affordable solution for low volume workloads, or as a backup analyzer. The test menu includes a variety of clotting assays, such as Lupus and APCR-V Leiden. The ACL 1000 also offers ba
The SYNCHRON CX4-S system consolidates DATs, TDMs and other esoteric tests in one workstation, targeted to the mid-size lab that processes 50-200 samples per day. Like all SYNCHRON CX super systems,
It takes powerful technology to increase laboratory efficiency and worker safety, and still lower costs. It takes the new SYNCHRON LX20 PRO, offering features that you will not find on any other chem
The leading fully automated system for plasma protein determinations. Third generation nephelometer combines reliability with highly cost-effective performance.
Medicine Products: